Original Article| Volume 159, P155-160, June 2021

Download started.


Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial


      • Excellent oncological long-term outcomes despite high proportion of patients with high-risk features.
      • Long-term quality of life after hyperthermic radiochemotherapy comparable with QoL of patients treated with radiochemotherapy alone.
      • More pronounced tumor regression seen in patients who achieved higher temperatures.



      The goal of the present study was to investigate the effect of deep regional hyperthermia on early and long-term oncological outcomes in the context of preoperative radiochemotherapy in rectal cancer.


      In this prospective phase II trial, patients with locally advanced rectal cancer were treated with 5-fluorouracil based preoperative radiochemotherapy with 50.4 Gy in 28 fractions. Deep regional hyperthermia was scheduled twice weekly. Pathological tumor regression was scored according to the Dworak regression system. The primary endpoint was pathological complete response (pCR). Further endpoints were local control (LC), distant control (DC), disease-free survival (DFS) and overall survival (OS). Hyperthermia was defined as feasible if 70% of patients received at least eight treatments. Quality of life was assessed at follow-up by the EORTC-QLQ-C30 and QLQ-CR29 questionnaires. Time to event data was analyzed according to Kaplan-Meier based on first-events. The study was registered on (NCT02353858).


      From 2012 until 2017, 78 patients were recruited. Median follow-up was 54 months. Based on magnetic resonance imaging, the mesorectal fascia was involved or threatened in 60% of the patients. Compliance with radiotherapy was 99%, 91% received both cycles of chemotherapy and 77% had eight or more hyperthermia treatments. Median time from the end of radiotherapy to surgery was 6.7 weeks. A pathological complete response was reported in 14% of the patients, 50% had either Dworak 4 (complete regression) or Dworak 3 regression (scattered tumor cells only). Three year estimates for OS, DFS, LC and DC were 94%, 81%, 96% and 87%. Patients with higher hyperthermia related cumulative temperatures showed stronger tumor regression. Global health status based on EORTC-QLQ-C30 was comparable with data from the general population.


      Deep regional hyperthermia was feasible, did not compromise standard treatments and resulted in promising long-term oncological outcomes and QoL.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • Rödel C.
        • Wittekind C.
        • Fietkau R.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • Guren M.G.
        • Undseth C.
        • Rekstad B.L.
        • Brændengen M.
        • Dueland S.
        • Spindler K.-L.
        • et al.
        Reirradiation of locally recurrent rectal cancer: a systematic review.
        Radiother Oncol. 2014; 113: 151-157
        • Lutgens L.C.
        • Koper P.C.
        • Jobsen J.J.
        • van der Steen-Banasik E.M.
        • Creutzberg C.L.
        • van den Berg H.A.
        • et al.
        Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial.
        Radiother Oncol. 2016; 120: 378-382
        • van der Zee J.
        • González D.
        • van Rhoon G.C.
        • van Dijk J.D.
        • van Putten W.L.
        • Hart A.A.
        Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.
        Lancet. 2000; 355: 1119-1125
        • Issels R.D.
        • Lindner L.H.
        • Verweij J.
        • Wust P.
        • Reichardt P.
        • Schem B.C.
        • et al.
        Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
        Lancet Oncol. 2010; 11: 561-570
      1. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995;345:540–3.

        • Varma S.
        • Myerson R.
        • Moros E.
        • Taylor M.
        • Straube W.
        • Zoberi I.
        Simultaneous radiotherapy and superficial hyperthermia for high-risk breast carcinoma: a randomised comparison of treatment sequelae in heated versus non-heated sectors of the chest wall hyperthermia.
        Int J Hyperthermia. 2012; 28: 583-590
      2. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M, Lutgens L, Lammering G, van Mastrigt GA, et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009:CD006269.

        • Zwirner K.
        • Bonomo P.
        • Lamprecht U.
        • Zips D.
        • Gani C.
        External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia.
        Int J Hyperthermia. 2018; 34: 455-460
        • Schroeder C.
        • Gani C.
        • Lamprecht U.
        • von Weyhern C.H.
        • Weinmann M.
        • Bamberg M.
        • et al.
        Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone.
        Int J Hyperthermia. 2012; 28: 707-714
        • Gani C.
        • Schroeder C.
        • Heinrich V.
        • Spillner P.
        • Lamprecht U.
        • Berger B.
        • et al.
        Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer.
        Int J Hyperthermia. 2016; 32: 187-192
        • Kang M.K.
        • Kim M.S.
        • Kim J.H.
        Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy.
        Int J Hyperthermia. 2011; 27: 482-490
        • Quirke P.
        • Steele R.
        • Monson J.
        • Grieve R.
        • Khanna S.
        • Couture J.
        • et al.
        Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial.
        Lancet. 2009; 373: 821-828
        • Bruggmoser G.
        • Bauchowitz S.
        • Canters R.
        • Crezee H.
        • Ehmann M.
        • Gellermann J.
        • et al.
        Quality assurance for clinical studies in regional deep hyperthermiaQualitätssicherung in der regionalen Tiefenhyperthermie.
        Strahlenther Onkol. 2011; 187: 605-610
        • Jones E.L.
        • Oleson J.R.
        • Prosnitz L.R.
        • Samulski T.V.
        • Vujaskovic Z.
        • Yu D.
        • et al.
        Randomized trial of hyperthermia and radiation for superficial tumors.
        J Clin Oncol. 2005; 23: 3079-3085
        • Dworak O.
        • Keilholz L.
        • Hoffmann A.
        Pathological features of rectal cancer after preoperative radiochemotherapy.
        Int J Colorectal Dis. 1997; 12: 19-23
        • Nolte S.
        • Waldmann A.
        • Liegl G.
        • Petersen M.A.
        • Groenvold M.
        • Rose M.
        • et al.
        Updated EORTC QLQ-C30 general population norm data for Germany.
        Eur J Cancer. 2020; 137: 161-170
        • A'Hern R.P.
        Sample size tables for exact single-stage phase II designs.
        Stat Med. 2001; 20: 859-866
        • Burton S.
        • Brown G.
        • Daniels I.R.
        • Norman A.R.
        • Mason B.
        • Cunningham D.
        MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?.
        Br J Cancer. 2006; 94: 351-357
        • Rödel C.
        • Graeven U.
        • Fietkau R.
        • Hohenberger W.
        • Hothorn T.
        • Arnold D.
        • et al.
        Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2015; 16: 979-989
      3. Fokas E, Strobel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, et al. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst. 2017;109.

        • Rombouts A.J.M.
        • Hugen N.
        • Elferink M.A.G.
        • Nagtegaal I.D.
        • de Wilt J.H.W.
        Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study.
        Ann Surg Oncol. 2016; 23: 3593-3601
        • Evans J.
        • Bhoday J.
        • Sizer B.
        • Tekkis P.
        • Swift R.
        • Perez R.
        • et al.
        452O - Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?.
        Ann Oncol. 2016; 27: vi149
      4. Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Sezak M, Ozkok S, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2018;105:1417–25.

        • Deng Y.
        • Chi P.
        • Lan P.
        • Wang L.
        • Chen W.
        • Cui L.
        • et al.
        Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: Final results of the Chinese FOWARC Trial.
        J Clin Oncol. 2019; 37: 3223-3233
        • Gérard J.P.
        • Azria D.
        • Gourgou-Bourgade S.
        • Martel-Lafay I.
        • Hennequin C.
        • Etienne P.L.
        • et al.
        Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
        J Clin Oncol. 2012; 30: 4558-4565
        • Schmoll H.J.
        • Haustermans K.
        • Price T.J.
        • Nordlinger B.
        • Hofheinz R.
        • Daisne J.F.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.
        J Clin Oncol. 2014; 32 (3501–3501)
        • Frey B.
        • Weiss E.M.
        • Rubner Y.
        • Wunderlich R.
        • Ott O.J.
        • Sauer R.
        • et al.
        Old and new facts about hyperthermia-induced modulations of the immune system.
        Int J Hyperthermia. 2012; 28: 528-542
        • Taylor F.G.M.
        • Quirke P.
        • Heald R.J.
        • Moran B.J.
        • Blomqvist L.
        • Swift I.R.
        • et al.
        Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.
        J Clin Oncol. 2014; 32: 34-43
        • Vironen J.H.
        • Kairaluoma M.
        • Aalto A.M.
        • Kellokumpu I.H.
        Impact of functional results on quality of life after rectal cancer surgery.
        Dis Colon Rectum. 2006; 49: 568-578
        • Guckenberger M.
        • Saur G.
        • Wehner D.
        • Thalheimer A.
        • Kim M.
        • Germer C.-T.
        • et al.
        Long-term quality-of-life after neoadjuvant short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer.
        Radiother Oncol. 2013; 108: 326-330
        • Gani C.
        • Bonomo P.
        • Zwirner K.
        • Schroeder C.
        • Menegakis A.
        • Rödel C.
        • et al.
        Organ preservation in rectal cancer - Challenges and future strategies.
        Clin Transl Radiat Oncol. 2017; 3: 9-15
        • Gani C.
        • Kirschniak A.
        • Zips D.
        Watchful waiting after radiochemotherapy in rectal cancer: when is it feasible?.
        Visc Med. 2019; 35: 119-123
        • Appelt A.L.
        • Pløen J.
        • Harling H.
        • Jensen F.S.
        • Jensen L.H.
        • Jørgensen J.C.R.
        • et al.
        High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
        Lancet Oncol. 2015; 16: 919-927
        • Garcia-Aguilar J.
        • Chow O.S.
        • Smith D.D.
        • Marcet J.E.
        • Cataldo P.A.
        • Varma M.G.
        • et al.
        Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
        Lancet Oncol. 2015; 16: 957-966
        • Bahadoer R.R.
        • Dijkstra E.A.
        • van Etten B.
        • Marijnen C.A.M.
        • Putter H.
        • Kranenbarg E.-K.
        • et al.
        Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 29-42
        • van der Valk M.J.M.
        • Marijnen C.A.M.
        • van Etten B.
        • Dijkstra E.A.
        • Hilling D.E.
        • Kranenbarg E.-K.
        • et al.
        Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial.
        Radiother Oncol. 2020; 147: 75-83